Enhong Chen - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Enhong Chen

Showing results (51-60 of 53) with videos related to

Pageof 6

Sort By:

You have reached the last page of results.This site can display upto 53 results.

Cancer Research|December 17, 2010

Dual functional monoclonal antibody PF-04605412 targets integrin alpha5beta1 and elicits potent antibody-dependent cellular cytotoxicityGang Li, Lianglin Zhang, Enhong Chen, et al.

Nature Communications|October 30, 2024

TamGen: drug design with target-aware molecule generation through a chemical language modelKehan Wu, Yingce Xia, Pan Deng, et al.

Cancer Research|January 8, 2011

Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapiesDana D Hu-Lowe, Enhong Chen, Lianglin Zhang, et al.

Pageof 6

Search research articles

Showing results (51-60 of 53) with videos related to

Sort By:

Pageof 6

You have reached the last page of results.This site can display upto 53 results.

Cancer Research|December 17, 2010

Dual functional monoclonal antibody PF-04605412 targets integrin alpha5beta1 and elicits potent antibody-dependent cellular cytotoxicityGang Li, Lianglin Zhang, Enhong Chen, et al.

Nature Communications|October 30, 2024

TamGen: drug design with target-aware molecule generation through a chemical language modelKehan Wu, Yingce Xia, Pan Deng, et al.

Cancer Research|January 8, 2011

Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapiesDana D Hu-Lowe, Enhong Chen, Lianglin Zhang, et al.

Pageof 6